Loading...
XTAE
ILX
Market cap221mUSD
Dec 04, Last price  
6,415.00ILS
1D
-0.06%
1Q
6.70%
Jan 2017
14,691.33%
Name

Ilex Medical Ltd

Chart & Performance

D1W1MN
XTAE:ILX chart
P/E
18.41
P/S
0.78
EPS
3.48
Div Yield, %
2.13%
Shrs. gr., 5y
2.17%
Rev. gr., 5y
7.74%
Revenues
920m
-1.13%
461,424,000432,823,000497,495,000518,943,000553,664,000601,134,000633,958,000946,452,0001,060,994,000872,544,000930,890,000920,371,000
Net income
39m
-23.39%
-22,211,00022,103,00031,105,00027,650,00037,403,00046,981,00060,257,000120,621,000197,480,000102,123,00050,885,00038,981,000
CFO
82m
+1.49%
22,268,00079,814,00045,175,00012,768,00075,962,00058,601,00084,887,000182,404,000270,676,00069,739,00080,432,00081,630,000
Dividend
Apr 07, 2024136.45 ILS/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Ilex Medical Ltd engages in marketing, selling, and supporting equipment, disposables, and reagents for laboratories and healthcare establishments in Israel and South Africa. The company offers in vitro diagnostic equipment and reagent systems to hospitals, clinics, and other medical institutions; molecular biology products for cancer screening, retro virus viral load, TB, STDs, and other infectious diseases; and equipment, disposables, and reagents for in vitro fertilization, as well as food and pharma industries. It also distributes and supports nucleic acid testing blood screening solutions to large-scale blood banks; provides pre/post analytics and robotics; and develops, markets, implements, and supports laboratory information systems. In addition, the company offers specialized product range that includes molecular diagnostics, critical care, and immunology products. Ilex Medical Ltd was founded in 1977 and is based in Petah Tikva, Israel.
IPO date
Jan 01, 1995
Employees
255
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT